Novo Nordisk will take a look at whether or not its GLP-1 medicine may also help folks with alcohol-associated liver illness, and, as a part of that, will research if the therapies will change the quantity of alcohol folks drink.
This seems to be the primary time the corporate is getting concerned in analysis to see if the booming class of GLP-1 diabetes and weight problems medicine can have an effect on substance consumption, a query that educational researchers have been probing however the pharmaceutical business has to this point averted.
The nine-month study will attempt three medicine alone and in mixtures towards placebo. The first final result being examined is change in liver scarring, or fibrosis, and one of many secondary outcomes is modifications in alcohol consumption. The information of the research was first reported by Bloomberg.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
Have already got an account? Log in
View All Plans
Get limitless entry to award-winning journalism and unique occasions.
Subscribe
